ļ :		36945	U.S. DEPARTMENT OF COMMERC Patent and Trademark Office
	SEARCH REQUEST FORM		
	Requestor's PANATA HOLD	CM1-8D66 Serial	69/112,041
	Date: 3-4-2000 P	Phone: (763) 256-7543	Art Unit: 142
	Search Topic: 1 Please write a detailed statement of search top terms that may have a special meaning. Give e please attach a copy of the sequence. You may	Xamples of relevent citations, authors, book	usada Satu 16 to 15
	PLEASE SEARCH A	CONJUGATE OF 2 OF	23 KMORE
	MONOCLONAL ANTIBODI	ES OF THE SAMIE S	SPECIES (Homocon)
	homodimer, homotr	med ONE DO MOR	E OF THE
	hamodimer, homoti	IMO) ONE OR MICE	DECTION AND
	HOMOGIMET, NOMOTH	NOT HAVE AN A	z REGIOTO III
		ヘッナン ベルバン・イン	1-1.011
	ASSERTS NO NAW ANTI- NEOPLASTIC ACTIVITY IN UNCONLUGATED FORM, BUT THE CONJUGATE		
	UNCONLUGATED FO	RM, Dui	T
	DOFS HAVE ANTIN	VEOPLASTIC ALTIVI	,
			\sim
	CLAIMS	ARE ATTACHED	J/8//4/3
		Thank	
	·		
	Point of Contact: Alex Waslawiw Technical Info. Specialist		1 52 t
	CM1 12C14 Tel: 308-4491		
		STAFF USE ONLY	;
D	Date completed: 3-19-01	Search Site	Vendors
S	earcher:	STIC	· _ IG
T	erminal time:	X CM-1	Y STN
Е	lapsed time:	Pre-S	Dialog
С	PU time:	Type of Search	APS
	otal time: S	N.A. Sequence	Geninfo
N	lumber of Searches:	A.A. Sequence	SDC
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
N	P.U 3-15-01	Structure	DARC/Questel

Hunt 09/112,041

=> d his

```
(FILE 'MEDLINE' ENTERED AT 08:23:58 ON 19 MAR 2001)
                 DEL HIS Y
          97082 S ANTIBODIES, MONOCLONAL+NT/CT
L1
          36481 S L1/MAJ
L2
L3
               9 S HOMOCONJUGATE?
L4
               1 S L3 AND L2
L5
               3 S L3 AND L1
                 E ANTINEOPLASTIC/CT
                 E E6+ALL
                 E 374+ALL
                E ANTICARCINOGENIC AGENTS/CT
                 E E3+ALL
                 E ANTITUMOR AGENTS/CT
L6
          63391 S ANTINEOPLASTIC AGENTS/CT
               0 S L6 AND L3
L7
            442 S L6 AND L2
\Gamma8
             10 S FC AND L8
L9
         205922 S SIGNAL?
L10
              17 S L8 AND L10
L11
          45513 S L6/MAJ
L12
              16 S L11 AND L12
L13
                 E SIGANAL TRANSDUCTION/CT
                 E E3+ALL
                E SIGANAL TRANSDUCTION/CT
                 E SIGNAL TRANSDUCTION/CT
                 E E3+ALL
L14
        1268035 S C4./CT
L15
         489925 S L14 (L) TH./CT
L16
              8 S L15 AND L9
              12 S L13 AND L15
L17
L18
              19 S L16 OR L17
=> d .med 118 1-19
     ANSWER 1 OF 19 MEDLINE
L18
ΑN
     2000424323
                     MEDLINE
DN
     20377422
TΙ
     Clinical trials of antibody therapy.
ΑU
     Glennie M J; Johnson P W
CS
     Tenovus Research Laboratory, The Cancer Sciences Division, Southampton
     University School of Medicine, General Hospital, Southampton, UK SO16
     6YD. mjg@soton.ac.uk
     IMMUNOLOGY TODAY, (2000 Aug) 21 (8) 403-10. Ref: 50 Journal code: AEA. ISSN: 0167-5699.
SO
CY
     ENGLAND: United Kingdom
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
     (REVIEW, TUTORIAL)
LA
     English
EM
     200011
EW
     20001103
     Much of the 25 years since Kohler and Milstein first described making
AΒ
                                                                            Page 21
```

=> d his

```
(FILE 'HOME' ENTERED AT 08:51:25 ON 19 MAR 2001)
     FILE 'WPIDS' ENTERED AT 08:51:31 ON 19 MAR 2001
L1
             904 S MONOCLONAL# (L) (CONJUGAT?)
             254 S CD19 OR CD20 OR CD21 OR CD22 OR HER2 OR HER 2
L2
           14133 S ANTINEOPLAS? OR ANTICANCER# OR ANTITUMOR# OR ANTITUMOUR#
L3
L4
            4932 S ANTI (2W) (TUMOR# OR TUMOUR# OR CANCER# OR NEOPLAS?)
L5
             102 S L1 AND (L3 OR L4)
L6
              12 S L1 AND L2
             112 S L5 OR L6
L7
L8
               7 S L7 AND SIGNAL?
=> d .wp 1-7
L8
     ANSWER 1 OF 7 WPIDS COPYRIGHT 2001
                                            DERWENT INFORMATION LTD
ΑN
     2001-091571 [10]
                         WPIDS
                         DNC C2001-027027
DNN
     N2001-069337
TΙ
     Novel inverted CCAAT box binding protein, and related nucleic acids,
     antibodies and specific ligands, useful for treating and preventing
     cancer.
     B04 D16 S03
DC
     BRONNER, C; HOPFNER, R; JELTSCH, J M; LUTZ, Y; MOUSLI, M; OUDET, P;
ΙN
     JELTSCH, J
PA
      (ASRE-N) ASSOC DEV RECH & GENETIQUE MOLECULAIRE; (ADER-N) ADEREGEM ASSOC
     DEV RECH EN GENETIQ
CYC
     22
     WO 2000078949 A1 20001228 (200110) * FR 114p
PΙ
        RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
         W: AU CA JP US
     FR 2795414
                   A1 20001229 (200110)
     WO 2000078949 A1 WO 2000-FR1747 20000622; FR 2795414 A1 FR 1999-7935
ADT
     19990622
PRAI FR 1999-7935
                       19990622
     WO 200078949 A UPAB: 20010220
     NOVELTY - Isolated polypeptide (I), designated ICBP90 (inverted CCAAT box
     binding protein) having a 793 residue amino acid sequence (S1), fully
     defined in the specification, is new.
           DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
     following:
           (1) a polypeptide (Ia) that:
           (a) has sequence (S1), or a 15, 26, or 174 residue amino acid
     sequence (S2, (S3), (S4), all fully defined in the specification;
           (b) is a variant of (a);
           (c) has at least 80, preferably 90 % homology with (a) or (b);
           (d) is a fragment of at least 5 consecutive residues from (a)-(c);
or
           (e) is a biologically active fragment of (a)-(c);
           (2) polynucleotide (II) that:
           (a) is a 2382, 45, 78, or 525 base pair sequence, all fully defined
     in the specification or their corresponding RNAs;
           (b) is the complement of (a);
           (c) has at least 80 % homology with (a) or (b);
           (d) hybridizes to (a)-(c) under highly stringent conditions; or
           (e) is a fragment of at least 15 nucleotides from (a)-(d);
           (3) recombinant vector for cloning (II) and/or expressing (I) or
```